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OObjectives: Multicriteria decision analysis (MCDA) has been suggested
by some researchers as a method to capture the benefits beyond qual-
ity adjusted life-years in a transparent and consistent manner. The
objectives of this article were to analyze the possible application of
MCDA approaches in health technology assessment and to describe
their relative advantages and disadvantages. Methods: This article be-
gins with an introduction to the most common types of MCDAmodels
and a critical review of state-of-the-artmethods for incorporatingmul-
tiple criteria in health technology assessment. An overview of MCDA is
provided and is compared against the current UK National Institute
for Health and Clinical Excellence health technology appraisal pro-
cess. A generic MCDA modeling approach is described, and the dif-
ferent MCDA modeling approaches are applied to a hypothetical
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ttp://dx.doi.org/10.1016/j.jval.2012.06.015ase study. Results: A comparison of the different MCDA approaches
s provided, and the generic issues that need consideration before the
pplication of MCDA in health technology assessment are examined.
onclusions: There are general practical issues that might arise from
sing an MCDA approach, and it is suggested that appropriate care be
aken to ensure the success of MCDA techniques in the appraisal pro-
ess.
eywords: decision making, health economics, health technology
ssessment, multiple criteria decision analysis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In the United Kingdom, the National Institute for Health and
Clinical Excellence (NICE) makes recommendations to the Na-
tional Health Service after assessing new and existing medical
technologies. The current practice of NICE health technology
appraisals is based on the incremental cost-effectiveness ratio
(ICER), that is, the incremental cost per quality-adjusted life-
year (QALY) gained by recipients of treatment. Even though
NICE considers other criteria (e.g., severity and life saving) along
with ICERs, there is concern that this approach may fail to cap-
ture other important sources of value [1–3]. In recognition of
his issue, NICE commissioned Professor Sir Ian Kennedy to
arry out a study on the relationship between innovation and
he value of the technologies [4]. Also, recent developments
uch as the Patient Protection and Affordable Care Act in Amer-
ca [5] and the UK Department of Health’s decision to use value-
ased pricing [6] indicate a paradigm shift toward transparency
n using other criteria along with the traditional cost-effective-
ess (C/E) analysis. Multicriteria decision analysis (MCDA)
ethods can support decision makers faced with evaluating
lternatives by taking into account multiple criteria in an ex-
licit manner [7]. They provide a structured and transparent
pproach to identify a preferred alternative by clear consider-
tion of the relative importance of the different criteria and the
erformance of the alternatives on the criteria. In fact, a num-
er of pharmaceutical drug manufacturers recommended the
* Address correspondence to: Praveen Thokala, The University of
DA, UK.
E-mail: p.thokala@sheffield.ac.uk.
098-3015 – see front matter Copyright © 2012, International Socie
ublished by Elsevier Inc.se of MCDA (in their submissions to Professor Sir Ian Kennedy)
ut recognized that further research is needed before their im-
lementation in the health technology appraisal process.
The main aspects of any MCDA method are 1) the alternatives
o be appraised, 2) the criteria (or attributes) against which the
lternatives are appraised, 3) scores that reflect the value of an
lternative’s expected performance on the criteria, and 4) criteria
eights that measure the relative importance of each criterion as
omparedwith others.MCDAapproaches can be classified broadly
nto three categories: value measurement models, outranking
odels, and goal, aspiration, or reference-level models [7]. Figure
shows these three methods.
Value measurement models
The degree to which one decision option is preferred over an-
other is represented by constructing and comparing numerical
scores (overall value). The scores are developed for each indi-
vidual criterion initially and aggregated into higher-level value
models. Almost everyone who has suggested using MCDA
methodology for health technology assessment (HTA) sug-
gested this approach [8–11]; however, this approach is not with-
out its constraints. Program budgeting and marginal analysis
[12–14] and analytic hierarchy process [15,16], another widely
used MCDA technique, are also similar to this value measure-
ment modeling approach.
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The alternatives are compared pairwise, initially in terms of each
criterion, to assert the extent of preference for one over the other
for that criterion. The preference information across all criteria is
aggregated to establish the strength of evidence favoring the se-
lection of one alternative over other. This approach is not widely
used in health care but could also be an appropriate alternative for
MCDA in HTA as it is based on direct comparison of the key char-
acteristics of the alternatives.
Goal, aspiration, or reference-level models
This approach involves derivation of the alternative(s) that is closest
to achieving the predefined desirable (or satisfactory) levels of
achievement for each criterion [17]. Value-based pricing [18,19], a
ethod to set the prices of drugs/treatments such that the ICER is
nder the relevantC/E threshold, canbebasedonmathematical pro-
ramming techniques similar to those used in this MCDA approach.
Incorporating multiple criteria in health technology
appraisals
Health policy decision makers internationally so far have been
considering cost-per-QALY ratios alongside other criteria, such as
equity and fairness and prioritization of interventions for vulner-
able populations, in a deliberativemanner [20]. An integrated ICER
that includes other sources of value has been proposed to allow
explicit incorporation of other criteria, such as societal prefer-
ences, disease severity, equity and benefits to caregivers, in the
existing ICER framework. Societal preferences relating to distribu-
tional justice captured from surveys have been proposed for inclu-
sion in the ICER calculations [21,22]. Explicit incorporation of eq-
uity in calculating ICERs for HTAs has also been considered
[2,23,24], but a need for further research has been identified [25]. A
hybrid method that supplements the current ICER evaluation for
NICE with a comprehensive benefits and value review has also been
proposed [1,8]. This approach attempts to capture the sources of
value not systematically considered at the present (such as innova-
tion, societal benefit, disease severity, unmet need, patient compli-
ance, and related benefits) by using different ICER thresholds for dif-
ferent comprehensive benefits and value scores [8].
Health care organizations in a few countries have made at-
tempts to incorporate different criteria into their decision-making
processes. For example, the Netherlands health care system used
four criteria (care must be necessary, effective, and efficient and
cannot be left to the individual’s own responsibility) for priority
setting, but it made the decision-making process rather complex
[26]. Some countries such as Belgium and France, in an attempt to
establish a relationship between financial constraints andmedical
need, have proposed to vary their pharmaceutical expenditure on
- Goal programming
- Heuristics
- Meta-heuristics
MCDA Outranking models
Goal, aspiration or reference models
Value measurement models
- Weighted Sum Method
- AHP
- PBMA
- ELECTRE
- PROMETHEE-GAIA
Fig. 1 – Classification of MCDA methods. AHP, analytic
hierarchy process; ELECTRE, ELimination Et Choix
Traduisant la REalité (ELimination and Choice Expressing
Reality); MCDA, multicriteria decision analysis; PBMA,
programme budgeting and marginal analysis;
PROMETHEE-GAIA, preference ranking organization
method for enrichment evaluations.the basis of patients’ medical need [27,28]. France classifies med-icines into three categories: essential, important, and conve-
nience, and French people receive 100% reimbursement for essen-
tial drugs, 65% for important drugs, and 35% for convenience
medication [28]. In South Korea, the Health Insurance Review and
Assessment service considers clinical benefit, C/E, budget impact,
reimbursement status in other countries, and other features that
might affect public health in determining whether a new drug
receives reimbursement [29].
MCDA has also been used to inform health care decisions [30–
2], setting priorities for HTAs [33], and other governmental issues
34,35]. The benefit-risk assessment of medicines, based on mul-
iple benefit and risk criteria including the trade-offs between the
enefits and the risks, was also performed by using MCDA [36,37].
CDA techniques have also been used for shared decisionmaking
etween patients and doctors in the evaluation and selection of
herapies, treatments, and health care technologies [38,39]. These
CDA techniques were said to identify and include the personal
references of the patient, but the complexity of the MCDA models
nd the time taken to complete themodelwerementioned as disad-
antages [40,41]. Program budgeting and marginal analysis
13,14,42], used for reallocation of scarce health care resources, is
imilar to MCDA methodologies. This method has received some
ttention in the health sector [12,43], but its success has been lim-
ted because of the complexity of the approach, large data require-
ents, and organizational barriers [44,45].
Despite thewidespread use ofMCDA in other health streams, it
s only recently that there have been studies that advocate the use
f MCDA for HTA. A framework utilizing a valuematrix was devel-
ped to include quantifiable components that are currently con-
idered in health decision making to promote transparent and
fficient health care decisionmaking [9]. This framework was also
inked to a qualitative assessment including six ethical and health
ystem–related components of decision to provide a tool for com-
iningHTA,MCDA, values, and ethics [10]. Health England Leading
rioritisation study also used MCDA to prioritize investment in
reventative health interventions [46].
Most of the proposed MCDA approaches, however, use the
ame technique (weighted sum approach), which may lead to the
esearchers/health professionals assuming that it is the only rel-
vant MCDAmethod. This article attempts to provide an overview
f the main MCDA methods available and the issues with their
mplementation in a technology appraisal process.
MCDA versus NICE Appraisal Process
This section compares the MCDA approach to the NICE appraisal
process. Although NICE is chosen as the example, the findings are
generalizable to other international health care decision-making
organizations. MCDA is aimed at supporting decision makers
faced with evaluating alternatives taking into account multiple
and often concurrent criteria. The MCDA process consists of the
following phases: problem identification and structuring, model
building and use, and the development of action plans [7]. The
appraisal process followed by NICE is divided into three phases:
scoping, assessment, and decision making through deliberation
by a committee that makes its recommendations on the basis of
evidence and experts’ and patients’ opinions.
TheMCDA process is comparedwith the current NICE technol-
ogy appraisal process as shown in Figure 2. The current NICE ap-
proach includes this problem-structuring process during the
“scoping” stage to set the predefined options (treatments, drugs,
etc.) and the key outcomes relevant for the appraisal process. The
criteria for NICE appraisals are defined in the methods guide [47],
not separately for each appraisal, but the scoping process allows
identification of other key issues (such as disease-specific out-
comes). The first two steps of the MCDA process, that is, identify-
ing alternatives and criteria, is known as problem structuring; this
1174 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 7 2 – 1 1 8 1is usually achieved by decision conferencing [48,49], which in-
volves the meeting of all the relevant stakeholders. It is antici-
pated, however, that the criteria included in the MCDA approach
would be based on criteria used by NICE. Thus, there is not much
difference between the current NICE scoping approach and the
first two steps of the MCDA process. It should be noted that the
current criteria used by NICE or other organizationsmay not fulfill
all the requirements of MCDA methods such as nonredundancy,
judgmental independence, completeness, operationality, and
measurability [7]. The criteria should be analyzed to ensure that
they are suitable for use inMCDAmodeling, for example, ensuring
that the criteria are not redundant to avoid double counting (e.g.,
efficacy/effectiveness and cost/effectiveness) when using value
measurement models.
It is in the decision-making stage that the MCDA and the
current NICE appraisal processes differ [50]. In the NICE ap-
Alternatives
Key Issues
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Stakeholder 
meetings
Conduct surveys
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Fig. 2 – MCDA and NICE technology appraisal processes. AC
determination; MCDA, multicriteria decision analysis; NHS,
Clinical Excellence.proach, the evidence regarding the alternatives is captured andpresented as a report (including a table of summary character-
istics comparing the interventions on the key criteria). An ap-
praisal committee then makes a decision in a deliberative man-
ner by using ICER and other criteria. In the MCDA approach, this
evidence needs to be quantified and input into mathematical
models to identify the best alternative(s). The manner in which
these models are built separates the different MCDA tech-
niques. Thus, criteria definition process is the primary starting
point for both approaches, and an MCDA model would build on
the existing criteria that NICE is using by applying the design
principles of MCDA. MCDA approaches can support rather than
replace the deliberative process already existent in NICE by add-
ing consistency and transparency through explicit scoring and
weighting of criteria. It should be noted that another key differ-
ence between the current NICE technology appraisal process
and the proposed MCDA approaches is the principle of “oppor-
MCDA Process
Define criteria
Choose relevant 
MCDA method
Performance scale 
values
Elicit weights
Aggregation
MCDA Modelling
Information 
synthesis
Sensitivity analysis
Robustness 
analysis
Challenging 
intuition?
Deliberation
NICE Appraisal Process
mission 
eholders
erature 
tation
 from 
mittee
ients in 
tings
ence
Consultation on provisional 
views (ACD)
Draft guidance (FAD) 
circulated for appeal
Appraisal committee 
reconsideration
Guidance issued direct to 
NHS, patients and public
Decision Making
praisal consultation document; FAD, final appraisal
onal Health Service; NICE, National Institute for Health and sub
 stak
nt lit
nsul
ation
com
 Pat
 mee
 Evid
D, ap
Natitunity cost.” NICE is charged with value for money across all of
c
t
v
t
i
c
e
a
t
v
1175V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 7 2 – 1 1 8 1health and social care; it needs to consider the costs and bene-
fits foregone from displaced activities and does so by using the
ICER threshold approach. The current ICER threshold approach
is based on using QALY as the measure of benefit and if other
criteria are to be included in benefits, the value of threshold will
need to be recalculated, that is, the opportunity costs of the
displaced intervention will be different with an MCDA approach
than with a cost-per-QALY approach as the opportunity cost
needs to be considered across all criteria for displaced activities.
Furthermore, this approach to estimate C/E, assessing the ben-
efits of a technology against the ICER threshold, could be inter-
preted as a decision-making framework than as a criterion (or
an aspect of benefit) in an MCDA model. Thus, this article does
not include opportunity costs and the case study is set up as a
decision between two drugs using the net benefit (NB) approach.
(A Hypothetical) Case Study
One of the objectives of this article was to analyze the possible
application of MCDA methods in HTAs. A case study is presented
in this section to show how different MCDA techniques can be
applied to NICE technology appraisals.
The case study presented in this section is based on a hypo-
thetical NICE technology appraisal process where a recommenda-
tion is needed to be made between two drugs A and B, where drug
A is the current intervention and drug B is the new intervention.
The characteristics of each of the drugs when compared against
the best standard care are shown in Table 1. The C/E of the drugs is
measured by using NB calculated assuming a willingness-to-pay
threshold of £20,000 per QALY; if C/E is used to make the decision,
drug Bwould be recommended over drug A; however, MCDA could
also be used to compare the drugs.
The three MCDA approaches mentioned in the Introduction
section have been applied to this case study and are described
below. Although the case study uses two interventions (current
intervention and new intervention), all the MCDA approaches
can be extended to include more interventions. It should be
noted that the criteria specified here are for demonstration pur-
poses only. The aim of this study was not to enter into a debate
on what criteria should be used and their definitions but to
compare different MCDA techniques for incorporating multiple
criteria into the decision process once the relevant criteria are
identified.
Before theMCDAmodels can be developed, the performance of
the alternatives (drugs A and B) against the specified criteria needs
to bemeasured in an objectivemanner. To achieve this, measures
(or scales) that can describe the desirability of achieving different
levels of performance for each criterion need to be identified. For
some criteria, such as patient compliance, where preferences
might be assumed to be linearly related to the attribute’s value,
Table 1 – Characteristics of the drugs in the appraisal
process.
Characteristics Drug A
zi(a)*
Drug B
zi(b)*
C/E (in terms of NB) £15,850 £25,600
Equity (%) 0.14 0.08
Innovation Innovative Less Innovative
Patient compliance (%) 0.93 0.85
Quality of evidence Good Good
C/E, cost-effectiveness; NB, net benefit.
* zi(a) and zi(b) are attribute values on the ith criterion for drug A
and drug B, respectively.the attribute value zi can be substituted for the performance on theriterion. In most cases, however, this needs to be modeled as
here is rarely such a simple linear relationship between attribute
alues (zi) and preferences. In such cases, a scale needs to be con-
structed to represent the performance of alternatives; it should be
noted that choosing the scales (usually ordinal or ordered-categor-
ical scales) to model these performance measures is not trivial. In
this article, it is assumed that scales to measure the performance
of the drugs on various criteria already exist and are specified.
Furthermore, it is assumedwithout loss of generality that all these
scores are defined in such a manner that increasing values are
preferred.
Henceforth, the performance levels of drugs A and B on the ith
criterion as measured on these scales are represented as perfor-
mance score values vi(a) and vi(b), respectively. For any criterion i,
performance score vi(a) is a nondecreasing function of the attri-
bute value zi(a); this could also be defined more generally for any
criterion i as vi f(zi) as the function f is the same for all alterna-
tives (drugs) keeping in line with the need for the performance
of the different alternatives to be measured in an objective
manner. The performance value scores are generally standard-
ized to 0 at worst outcome and to a convenient value (usually 1,
10, or 100) at the best outcome.
The three different MCDA approaches mentioned are applied
to this case study as below; this allows us to demonstrate the
potential advantages and pitfalls of using the different MCDA
modeling approaches.
Value measurement models
This approach is based on constructing a single overall value for
each alternative to establish a preference order of alternatives. An
alternative A is said to be preferred to B if V(a)  V(b), where V(a)
and V(b) are overall values (taking into account all n criteria) of A
and B, respectively. Also, there is said to be indifference between
the alternatives if V(a)  V(b).
The first step in this approach is to do preference modeling,
that is, constructing the performance levels of drugs A and B on all
criteria as shown in Table 2. The performance score values vi(a)
and vi(b) of drugs A and B on the ith criterion, also known as partial
value functions, are bounded between 0 (worst outcome) and 1
(best outcome). The importance of different criteria can be mea-
sured by using the gain associated with replacing the worst out-
come by the best outcome, and the weights wi represent the rela-
ive importance of the ith criterion. Weights are assigned
ndependently of the alternatives to provide consistency across
omparisons, and scores for each criterion are then assigned for
ach alternative. Furthermore, the weights can be normalized to
llow interpreting of theweight of individual criterion as a propor-
ion of the total weight. The final step is to aggregate these partial
alue functions taking into account the relative importance of dif-
Table 2 – Performance levels of drugs.
Criterion (i) Drug A
vi(a)*
Drug B
vi(b)*
Weights
i
C/E 0.72 0.84 8
Equity (%) 0.14 0.08 1
Innovation 0.91 0.62 3
Patient compliance (%) 0.93 0.85 2
Quality of evidence 0.82 0.79 3
C/E, cost-effectiveness.
* vi(a) and vi(b) are performance value scores on criterion i for drug
A and drug B, respectively.
† i is the weight of criterion i.
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ent value measurement approaches.
In this article, additive aggregation (also known as weighted
sum approach) is described as it is the most common value mea-
surement modeling approach [7] and it is based on the following
equation:
V(a)
i1
n
wivia (1)
here V(a) represents the overall value, wi represents the relative
mportance, and vi(a) represents the score of alternative A on the
th criterion, respectively.
This approach requires some assumptions regarding the crite-
ia and their weights, namely, preferential independence of crite-
ia and the need for the weights to satisfy the trade-off require-
ents. Preferential independence requires that the decision can
e made by using a subset of criteria if the other criteria are the
ame for all alternatives irrespective of their actual values; that is,
he decision can be made by using only the criteria on which the
lternatives differ. The weight parameterswi also need to follow a
trict trade-off condition to capture the concept of “importance” as
ell as compensate for the different measurement scales of dif-
erent criteria. This is achieved by swing weights, which represent
he gain in overall value by going from the worst value to the best
alue in each criterion; that is, for any two criteria i and k, the ratio
i/wk is the change in vk(a) that should compensate for a unit loss
n vi(a). There are a number of ways in which these swing weights
can be elicited; these techniques are not discussed here as they are
explained in detail in the literature [7].
In this case study, it is assumed that the relative weights and
the performance of the alternatives on different criteria have been
identified by using appropriate techniques and are as shown in
Table 2. Using this information, the overall values of drugs A and B
can be calculated as follows:
Va 8 0.72 1 0.14 3 0.91 2 0.93 3 0.82 12.95
(2)
Vb 8 0.84 1 0.08 3 0.62 2 0.85 3 0.79 12.73
(3)
f the decision was made by using this approach, drug A would be
ecommended over drug B as the aimof this approach is to identify
he alternative with maximum value. Drug A has a higher overall
alue due to the higher weights i placed on innovation, compli-
ance, and quality of evidence inwhich drugAperforms better than
drug B.
This approach is simple to use, but as observed in this scenario,
poor performance on a criteria (C/E) can be overcome by doingwell
in other criteria depending on the weights and partial value func-
tions. Also, considerable caution needs to be taken to satisfy the
Table 3 – Performance scores of drugs.
Criterion (i) Drug A
vi(a)*
Drug B
vi(b)*
C/E 0.72 0.84
Equity (%) 0.14 0.08
Innovation 0.91 0.62
Patient compliance (%) 0.93 0.85
Quality of evidence 0.82 0.79
C/E, cost-effectiveness.
* vi(a) and vi(b) are performance value scores on criterion i for drugA and drug B, respectively.preferential independence of criteria and the corresponding
trade-offs of swing weights.
Outranking approach
This principle of outranking is based on the general concept of
dominance [51,52]. If the performance of two alternative drugs A
and B on each of the i criteria is vi(a) and vi(b), respectively, we can
conclude that drug A should be preferred over drug B if vi(a) vi(b)
for all criteria (with strict inequality for at least one criterion). In
this event, drug A is said to dominate drug B. Strict domination,
however, rarely occurs in practice, and thus the evidence needs to
be evaluated in a systematic manner. More generally, drug A out-
ranks alternative drug B if there is sufficient evidence to justify a
conclusion that drug A is at least as good as drug B, taking all
criteria into account.
This approach utilizes outranking relation (i.e., comparing per-
formance scores on individual criterion to see which alternative
outranks the other on that criterion) on a set of alternatives focus-
ing on pairwise comparisons, and these pairwise comparisons are
used to estimate the concordance and discordance indices. For
drug A, concordance index is the evidence in favor of A outranking
B while the discordance index is the evidence against A outrank-
ing B. Similarly, for drug B, the concordance index is the evidence
in favor of B outranking A while the discordance index is the evi-
dence against B outranking A.
The first step in estimating the concordance and discordance
indices is to construct a matrix of outranking relations from the
individual scores on each criterion. The performance scores of
drugs against the individual criteria are shown in Table 3while the
matrix of outranking relations along with the relative weights for
different criteria is shown in Table 4. The outranking approach
recognizes that performance scores, vi(a) and vi(b), are imprecise
measures, and so alternative a is preferred to alternative b only if
vi(a) – vi(b) exceeds a predefined “indifference threshold.” For ex-
ample, if the threshold was 0.05, alternative drug A and drug B
would be incomparable on “quality of evidence” criteria as the
difference 0.03 is less than the threshold. The indifference thresh-
olds can be specified for the difference in either performance value
scores vi(a) or the attribute values zi(a). Also, it is to be noted that the
weightsofdifferent criteria areuninfluencedby the scaleof thevalue
functions and thus do not need to follow the theoretical concept of
trade-offs as required by the valuemeasurement approach; they just
represent the relative importanceof different criteria in theassertion
that one alternative is better than the other.
There are a number of ways to quantify concordance and dis-
cordance indices that correspond to different outranking meth-
ods. In this study, ELECTRE I [53] is used but the reader should bear
in mind that there are a number of other options (ELECTRE II, III,
IV, TRI [51,52,54], PROMETHEE [55], and GAIA [56]). In ELECTRE I,
the concordance index is defined as the ratio of the sumofweights
in the criteria for which drug A is at least as good as drug B to the
sum of weights in all criteria, that is,
iQ(a, b)i
Table 4 – Outranking relations and weights.
Criterion (i) Weights i* Drug A Drug B
C/E 10 ✓
Equity (%) 2 ✓
Innovation 1 ✓
Patient compliance (%) 3 ✓
Quality of evidence 2 — —
* i is the weight of criterion i.C(a, b)
i1m i
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1177V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 7 2 – 1 1 8 1where Q(a, b) is the set of criteria for which A is at least as good as
B. For the discordance index, a veto threshold ti can be specified as
follows:
D (a, b)1 if vi(b) vi(a) ti for any i0 otherwise
The concordance and discordance indices are compared against
the concordance (C=) and discordance (D=) thresholds, respectively,
to estimate the outranking relation. If the concordance index (C) is
greater than the concordance threshold (C=) and the discordance
index (D) is less than the discordance threshold (D=), then that drug
is said to outrank the other drug. If the thresholds are specified
such that both drugs outrank each other, then they are said to be
indifferent. In case of neither drug outranking the other, the drugs
are said to be incomparable. If there are more than two alterna-
tives (i.e., A, B, C, etc.), the concordance and discordance indices
are estimated for each pair to build an outranking relation by using
the concordance and discordance thresholds C= and D=, respec-
tively.
In the current case study, the concordance index of drug A
against drug B is the sum of weights in Q(a, b), set of criteria for
which A is at least as good as B, divided by the overall sum of
weights; that is, (2  1  3  2)/(10  2  1  3  2)  8/18. The
ecision, however, can be vetoed by the poor performance of drug
in C/E by specifying the veto threshold t1 as 0.1 for C/E (drug B is
etter than A in C/E by 0.12, which is greater than the veto thresh-
ld t1). Similarly, the concordance index of drug B against drug A is
10/18. If the concordance threshold (C=) is less than 0.56, drug B is
said to outrank drug A provided the veto thresholds for other cri-
teria are not violated as the concordance index is greater than the
concordance threshold.
This method does not need the theoretical requirement of
trade-offs for weights as required in the valuemeasurementmod-
els; the weights just convey the relative importance of the differ-
ent criteria. This method is intuitive, and the use of indifference
and veto thresholds allowsmore flexible/realistic decision rules to
be specified. There are different levels of complexity—ELECTRE I,
II, III, IV, TRI, PROMETHEE, and GAIA—in the outranking approach.
This approachmight lead to incomparability if two drugs are quite
similar; however, one could argue that this is appropriate for the
appraisal process as further deliberation might be needed to
choose between the drugs if their performance is quite similar.
Goal programming
Goal programming involves a mathematical formulation of the
satisficing heuristic; the term “satisficing” is a combination of the
terms “satisfy” and “suffice.” The emphasis of the satisficing
model is on attaining satisfactory levels of performance on each
criterion, considering the preference of criteria in their order of
importance. Satisficing levels are predefined as “goals,” and a pro-
gramming algorithm is used to identify the alternatives that sat-
Table 5 – Attributes of drugs, the goals and weights agains
Criterion (i) Drug A
zi(a)*
Drug
zi(b)
C/E £15,850 £25,60
Equity (%) 0.14 0.08
Innovation Innovative Less Inno
Patient compliance (%) 0.93 0.85
Quality of evidence Good Good
C/E, cost-effectiveness.
* zi(a) and zi(b) are attribute values on criterion i for drug A and drug
† i and i are the weights attached to the deviations from the goisfy the goals in the specified priority order [57].Unlike theweighted sum approach, which involves developing
partial value functions via, the goal programming method oper-
ates directly on the attribute values, zia, of the alternatives on the
criteria, as it is more operationally meaningful to match measur-
able attributes to the goals. The attribute values of alternative A
corresponding to the “n” criteria are represented as z1a,z2
a,...,zna while the “goals” for each criterion are represented as
g1,g2,...gn as shown in Table 5. These goals (“aspiration levels”) are
sually defined by the decision maker and are understood as de-
irable levels of performance for each attribute value.
Direction of preference in a goal programming context repre-
ents the relationship between the attribute value and the goal.
hree alternatives for the direction of preferences can be found: 1)
hen the attribute is maximized, the goal’s level of performance
chieves a minimum representing a point of “satisfaction,” for
xample, attaining at least 95% patient compliance; 2) when the
ttribute is minimized, the goal’s level of performance achieves a
aximum representing a point of “satisfaction,” for example, the
CER threshold of nomore than £20,000 per QALY; and 3) when the
ecision makers define a most desirable level of performance for
he attribute that must be as close to the goal as possible. The
ifference between the attribute values and the goals are repre-
ented as goal deviations di
 or di
, that is, the amounts a targeted
goal is exceeded or underachieved, respectively.
Goal programming involves minimizing the goal deviations
taking the relative importance of goals into account. There are two
main variants of goal programming [58]—weighted goal program-
ming and lexicographic goal programming; they differ in the way
the optimal solution is prioritized and achieved. The weighted
goal programming approach minimizes the unwanted deviations
after assigning weights to the goal deviations according to their
relative importance as shown in the following equation:
min D
i1
n
(i
di
i
di
)
ubject to fix di di gi for i 1, ...,n
here x is the set of decision variables (independent) to be deter-
ined, fix is the attribute value zia as a function of the indepen-
ent variable(s), gi is the target value for the ith criterion, di
 and
i
 are the negative and positive deviations from this target value,
nd i
 and i
 are the respective weights attached to these devia-
tions. The lexicographic goal programming formulation orders the
goals into a number of priority levels and minimizes them in a
lexicographic manner, that is, deviation in a higher priority level
beingmore important than any deviations in lower priority levels.
This sequential minimization approach minimizes each priority
while maintaining theminimal values reached by all higher prior-
ity level minimizations by adding them as explicit constraints.
In this case study, it was assumed that patient compliance and
equity are difficult to change but C/E can be improved by changing
the price of the drug (akin to value-based pricing). As C/E is the
ferent criteria.
Goals
gi
Weights
i
†
Weights
i
†
£20,000 10 0
0.20 0 5
— 0 0
0.95 0 5
— 0 0
pectively.
or criterion i.t dif
B
*
0
vative
B, resonly attribute that can be changed, it does not matter whether a
i
t
a
c
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approach is utilized. In this study, the lexicographic GP approach
s used with C/E as the highest priority and all the other criteria
ogether as the next priority. Assuming the NB for drug A varies
ccording to f(x) 25,000 – 1000x (where x is the unit price of drug
A), the price of drug A has to be decreased by 45% (from the initial
price of £9.15 to £5.00) so that the C/E goal of an NB of £20,000 is
achieved. The NB for drug B is already above the specified goal
threshold. In reality, an NB higher than £20,000 would be encour-
aged by the decision makers but for this case study the NB target
represents the minimum requirement.
Now that both drugs have achieved the target C/E, the analysis
can move to the next priority level, which includes all the other
criteria. From Table 5, it can be seen that the only two criteria that
have aweight value other than zero are equity w2 5 and patient
ompliance w4  5; therefore, the negative deviations d2 and d4
are to be calculated as follows:
Drug A
d2
a g2 z2a 0.2 0.14 0.06 (4)
d4
a g4 z4a 0.95 0.93 0.02 (5)
Drug B
d2
b g2 z2b 0.2 0.08 0.12 (6)
d4
b g4 z4b 0.95 0.85 0.1 (7)
Thus, the deviations for drug A and B are
Da 5 0.06 5 0.02 0.4 (8)
Db 5 0.12 5 0.1 1.1 (9)
Drug A performs better than drug B in terms of getting closer to
the equity and compliance goals; thus, it could be recommended
on the condition that its price is reduced by 45% (to ensure that
drug A satisfies the C/E goal).
Table 6 – Comparison of different MCDA approaches.
Value measurement models
Weights Swing weights are used to capture b
the effect of measurement scales
the importance of the criteria
Weights need to satisfy the
preferential independence of crite
and the trade-off requirements
Measuring the performance
of the criteria
Performance scores vi(a), monotonic
functions of the attribute values z
need to be developed for all criter
i. Significant effort is needed to
develop these performance scores
Complexity of the MCDA
model
Weighted sum approach is easy to
understand and use by the decisio
makers. The parameters can be
changed in real time to observe th
effect
Presentation of the results Easy to follow and enables further
deliberation, well suited for good
visual presentation of the results
Incorporating uncertainty Probabilistic sensitivity analysis can
used to propagate parameter
uncertainty quite easily.MCDA, multicriteria decision analysis.Another variation to this approach is to have a range of goals
based on other criteria. For example, the C/E could have different
thresholds based on the alternative’s performance on other crite-
ria [8]. In practice, this could be implemented by using a higher
threshold if the aggregated goal deviations for other criteria are
low; that is, a technology could be assigned a higher ICER thresh-
old (as it performs better in achieving close to other goals).
This goal programming approach echoes similarities with val-
ue-based pricing [18,19], in which mathematical programming
techniques can be used to estimate the price of the drug, based on
the definition of “value” chosen by the health organizations. Also,
obviously, f(x) will never be as simple as our assumption, and so
complex C/E models need to be built and analyzed to identify the
price of the drug such that the ICER is under the recommended
value-based threshold. It should be noted that a number of heu-
ristics have been developed to deal with complexity as the com-
putational time for a goal programming problem is directly related
to complexity.
Comparing Different MCDA Approaches
Table 6 compares the different MCDA approaches on a number of
dimensions to provide an indication of the potential benefits and
limitations of each of the approaches. First, there are different
requirements of the weights depending on the MCDA approach,
with value measurement models requiring additional effort com-
paredwith outranking and goal programmingmethods because of
the time needed to interpret swing weights. Similarly, value mea-
surement models need significant effort to develop the perfor-
mance value scores while the goal programming and outranking
methods can be implemented on the attribute values directly.
Valuemeasurementmodels, however, are easy to understand and
can enable real-time sensitivity analysis. Both outranking and
goal programming methods are easy to follow, but significant
computational time is needed for goal programming. Similarly,
Outranking approach Goal programming
Weights are uninfluenced by the
scale of the value functions.
They convey the relative
importance of criteria in the
assertion that one alternative
is better than the other
Weights do not have to satisfy
any conditions
Weights are attached to the
deviations and represent
the relative importance of
criteria by specifying an
overall measure of
deviations from the goals
Weights do not have to
satisfy any conditions
Outranking approach can use
either performance value
scores vi(a) or the attribute
values zi(a), saving on the
effort needed to develop
performance scores
Goal programming method
operates directly on the
attribute values, zi(a). No
need to develop
performance scores.
Intuitive and easy to follow. With
right software, assumptions
can be changed and results
can be observed almost
instantaneously
Easy to understand but
requires significant
computational time to
provide results. Real-time
updating is not possible
Moderately easy to follow, can be
presented visually but difficult
with multiple alternatives
Results easy to follow, but
they cannot be
represented visually
Moderately difficult to include
uncertainty, needs specialist
software
Quite difficult to include
uncertainty, complex
stochastic programming
techniques are neededoth
and
ria
i(a),
ion
n
eir
be
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visual presentation while results from outranking and goal pro-
gramming methods are difficult to follow. Finally, uncertainty is
easier to incorporate in value measurement models than in out-
ranking or goal programming approaches.
Generic Issues with Using MCDA
The potential issues that might arise with implementing any
MCDA approach in the HTA process are detailed in the following
subsections.
Appraisal-specific or generic process
TheMCDA process could be the same for all technology appraisals
or it could be tailored to a given appraisal under consideration. For
example, the criteria (and their weights) can be different for each
appraisal or the same set of criteria can be used for all apprais-
als. Furthermore, the functions that estimate the value of alter-
natives against the criteria could be fixed for all the appraisals
or appraisal-specific functions could be built on the basis of
appraisal characteristics. The chosen MCDA method needs to be
transparent, consistent, auditable, and defendable as it is a na-
tional decision-making process. Thus, appropriate care needs to
be given before deciding on an appraisal-specific process or a stan-
dard approach for all the appraisals. Committee members’ prefer-
ences or societal preferences need to be used as weights on the
basis of whether an appraisal-specific or generic MCDA process is
chosen, respectively.
If an appraisal-specific MCDA approach is chosen, the weights
are elicited from the committee members. The weights (i.e., pref-
erences of the individual decision makers) can be captured in a
workshop setting by using deliberation, by direct rating of alterna-
tives (such as visual analogue scales analytic hierarchy process,
ranking, and point allocation), or by indirect weight elicitation
methods such as discrete choice experiments [59–61]. As the de-
cision committee includes a number of individuals from different
perspectives (patients, clinicians, administrators, etc), there can
be issueswith group dynamics in the collection and aggregation of
the individuals’ preferences (i.e., criteria weights). Variations are
expected across decision makers according to their perspective
and value systems (e.g., a patient might see safety as more impor-
tant than efficacy and the contrary for a clinician). MCDA can ad-
dress this variation by allowing each individual on a committee to
express his or her perspective and aggregating the weights, with
the method for aggregation of individuals’ preferences dependent
onwhether a consensus needs to be achieved by the committee. If
a consensus is necessary, the individuals in the committee need to
share/compare their values to identify issues of conflict and
achieve common ground, which can be difficult to achieve. Other-
wise, the overall value can be calculated as an average of the indi-
vidual values, which could be anonymous if need be. This varia-
tion can be represented as the SDs associated with the mean
values of theweights, and sensitivity analysis can be performed to
see the robustness of results to changes in the weights.
If a generic MCDA approach is chosen, the weights need to be
elicited from the general population, which requires a large num-
ber of resources to capture the population preferences. The selec-
tion of the criteria needs to be made apriori by the policymakers.
Furthermore, it needs to be ensured that the general population
understands (and interprets) the meaning of the weights and the
value scores correctly. Consistency in the MCDA process across
different appraisals and over time can be achieved by clearly de-
fined criteria and the weights estimated from the public in ad-
vance. In this approach, the role of the appraisal committees for a
given appraisal would be to interpret the evidence regarding char-
acteristics of the relevant diseases, patients, and interventions ofinterest and to assess which of the criteria apply and how they
should be valued. The decision makers use MCDA to evaluate the
data and context to come up with a decision, which is similar to
the deliberative process in current practice. Given the consider-
able resources needed to estimate general population preferences,
it might be better to build the population consultation on some
exploration at the committee level, provided the committees are a
good representation of the general population.
Uncertainty modeling
There are three main areas of uncertainty involved with using
MCDA in the HTA process, namely, uncertainty in problem
structuring (i.e., choosing the right MCDA model, criteria, level
of detail, etc.); uncertainty with evidence of different alterna-
tives; and variation in preferences (i.e., uncertainty in perfor-
mance scores, criteria weights, thresholds, etc.). Structural un-
certainty is hard to capture and is out of the scope of this article.
The uncertainty in clinical effectiveness and C/E as well as other
evidence (usually caused by extrapolating the data from a ran-
domized controlled trial to a general population) has a direct
effect on committee members’ preferences; thus, it should be
ensured that they understand this uncertainty in evidence. Sce-
nario analyses [62], multiattribute utility theory [63], fuzzy logic
[64], and stochastic multicriteria acceptability analysis [65] can
be used to capture this uncertainty. Variation in criteria values,
weights, and thresholds evident during the aggregation of the
preferences of individuals in the decision committee can be
represented by using SDs associated with themean values. Sen-
sitivity analysis can be performed to see the robustness of re-
sults to changes in the model parameters. Because of the inter-
dependence of uncertainty with evidence of different
alternatives and variation in committee members’ preferences,
appropriate care needs to be taken in performing uncertainty
analysis. Probabilistic sensitivity analysis can also be used to
capture and propagate the parameter uncertainty with the help
of Monte-Carlo simulation techniques [66,67].
Practical issues
The practicality of applying MCDA will involve a significant
workload/cognitive burden on decision makers. Appropriate
thought needs to be given to the practical aspects such as
whether to train all the committee members in the relevant
techniques of MCDA or whether to have a facilitator(s) to help
use the techniques in the decision process. Also, the MCDA
techniques rely on preference capturing, statistical analysis,
and synthesizing data, whichmay require specialist software or
programs; thus, the relevant software/program requirements
need to be identified. This also relates to other practical issues
such as the methods of data capturing (survey sheets on paper,
computer-based forms, etc.) and data aggregation. Data aggre-
gation involves capturing the individual committee members’
preferences and transferring them into appropriate software;
this could be done in real time or in between the meetings. The
MCDA model developed needs to be explored to ensure the ro-
bustness of key factors; this can be performed premeeting, dur-
ing themeeting, or postmeeting depending on the availability of
the MCDA facilitator. Finally, the model outputs need to be vi-
sualized and incorporated into the final documentation along
with the recommendations. All these aspects involve significant
burden on decision makers, and it needs to be decided whether
the transparency and consistency achieved by using the MCDA
process is worth the additional burden.
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An overview of theMCDA process is provided and is identified to
be similar to the existing NICE appraisal process but with the
addition of a formal mathematical approach to decision mak-
ing. The main MCDA modeling approaches are applied to a hy-
pothetical case study, and their potential strengths and weak-
nesses are outlined. The potential users need to understand the
general practical issues that might arise from using an MCDA
approach in the HTA process and choose an appropriate MCDA
method to ensure the success of MCDA techniques in the ap-
praisal process.
Source of financial support: This research has received finan-
cial support from the NICE Decision Support Unit, but NICE had no
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